StockDrifts LogoStockDrifts

Sama Pharmaceutical 009300

Company
삼아제약Sama Pharmaceutical
Insiders
1
Buys
9
Total Value
₩20M ($14K)
Avg Return
-10.58%
Last Filing
2025-08-19

Sama Pharmaceutical (009300) has 9 disclosed insider purchases and 0 disclosed disposals on record, filed by 1 distinct insiders. Together those filings cover ₩20M ($14K) in reported transaction value. The earliest filing StockDrifts holds for Sama Pharmaceutical is dated 2025-07-11; the most recent is 2025-08-19. Across these filings the average return since disclosure is -10.58%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-08-19BUYMarket Buy
황종숙
Hwang Jong-suk
moving105₩16,900-3.2%₩2M ($1K)
2025-08-07BUYMarket Buy
황종숙
Hwang Jong-suk
moving78₩18,010-9.2%₩1M ($976)
2025-07-30BUYMarket Buy
황종숙
Hwang Jong-suk
moving61₩18,300-10.6%₩1M ($775)
2025-07-29BUYMarket Buy
황종숙
Hwang Jong-suk
moving73₩18,340-10.8%₩1M ($930)
2025-07-25BUYMarket Buy
황종숙
Hwang Jong-suk
moving50₩18,420-11.2%₩921K ($640)
2025-07-22BUYMarket Buy
황종숙
Hwang Jong-suk
moving50₩18,640-12.2%₩932K ($647)
2025-07-18BUYMarket Buy
황종숙
Hwang Jong-suk
moving90₩18,730-12.7%₩2M ($1K)
2025-07-16BUYMarket Buy
황종숙
Hwang Jong-suk
moving27₩18,590-12.0%₩502K ($349)
2025-07-11BUYMarket Buy
황종숙
Hwang Jong-suk
moving571₩18,890-13.4%₩11M ($7K)

Frequently asked questions

Who has been buying Sama Pharmaceutical stock?
1 distinct insiders have filed 9 disclosed insider purchases in Sama Pharmaceutical (009300), most recently on 2025-08-19. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Sama Pharmaceutical have?
Sama Pharmaceutical has 9 buy-side and 0 sell-side disclosures on record, covering ₩20M ($14K) in total reported value, spanning 2025-07-11 to 2025-08-19.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.